Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Cash from Financing Activities (2024 - 2025)

Historic Cash from Financing Activities for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $14.7 million.

  • Neuphoria Therapeutics' Cash from Financing Activities rose 1324270.81% to $14.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $19.8 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2025, which is 8988.49% down from last year.
  • Latest data reveals that Neuphoria Therapeutics reported Cash from Financing Activities of $14.7 million as of Q4 2025, which was up 1324270.81% from $3.3 million recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' Cash from Financing Activities ranged from a high of $14.7 million in Q4 2025 and a low of -$227338.0 during Q3 2024